Cancer Honor Roll of Donors - Support UCSF

x
1
7
Honor Roll
of Donors
2011–2012
2
3
4
5
6

Year in Review
Top Accomplishments
One-Two Punch to Prostate Cancer
Dear Friends,
Each of you has a personal story to tell about why you support our fight
against cancer. And we are driven to succeed, every day, by those stories –
and by your belief in our work.
Some of the most powerful stories are from donors deeply grateful for a
doctor’s care and commitment to eradicating cancer. Their philanthropy, in
turn, fuels the research of our physician-scientists in ways simply not possible
without such support. We highlight a few of these partnerships in this honor
roll. While the details of your own experience may differ, the importance of
your philanthropy is the same.
Your generosity has allowed us to make some incredible leaps in our understanding
of the disease, advance our march toward new treatments, and offer
fresh hope to those stricken by cancer. Indeed, the list of what we’ve been
able to accomplish just this year is too long to include here. But we did want
to share a few of the most exciting innovations and introduce you to three
new researchers (see right). You’ll see that we’re quickly gaining insights into
the molecular basis of cancer and translating those findings into new ways to
attack the disease.
Thank you from all of us at the UCSF Helen Diller Family Comprehensive
Cancer Center. Together, we look forward to writing a rapid ending to the story
of cancer.
Frank McCormick, PhD, FRS
Director, UCSF Helen Diller Family Comprehensive Cancer Center
E. Dixon Heise Distinguished Professor in Oncology
David A. Wood Distinguished Professor of Tumor Biology and Cancer Research
In the past year alone, UCSF has transformed the fight against prostate cancer.
Davide Ruggero, PhD, reported in Nature his discovery of the mechanism that triggers
metastasis in prostate cancer and perhaps other cancers. Ruggero found that mTOR,
a molecule that regulates cell growth and division, goes awry in prostate cancer.
mTOR alters the synthesis of a specific group of proteins that make the cancer cells
invade normal organs. The discovery holds promise for new treatments to shut down
the process. Just four months later, Charles Ryan, MD, reported on the success of a
new drug, abiraterone acetate (marketed as Zytiga) in slowing the spread of metastatic
prostate cancer. During the UCSF-led trial, the drug was so effective that the study
was “unblinded” midway, allowing patients receiving the placebo to instead take
Zytiga. Not only did the drug slow the deterioration associated with the disease, but it
increased the time prostate cancer patients spent without pain.
Decoding the Disease
UCSF is at the forefront of a paradigm shift in combating cancer, one predicated
on sophisticated new tools used to sequence the DNA of patients’ tumors. Called
precision medicine, the new field matches patients with treatments known to be
effective for their type of tumor. Recent additions to the faculty have secured our
place at this new frontline. Using genetic analysis, Boris Bastian, MD, PhD, was the
first to identify several key mutations in melanoma, which are now routinely tested
for in patients and used for selecting the appropriate treatment. Barry Taylor, PhD,
has successfully used computer programs to search for patterns in the genome of
prostate tumors that may predict recurrence. And Trever Bivona, MD, PhD, has put his
doctorate in molecular and cellular biology to good use in his discovery of a protein,
AXL, that drives resistance to an important lung cancer drug.
Fighting Tumors with Tumors
Neurosurgeon Andrew Parsa, MD, PhD, is fighting fire with fire. His brain cancer
vaccine, crafted from patients’ own tumors, is extending lives by several months or
longer in phase 2 clinical trials. The patients studied suffer from recurrent glioblastoma
multiforme – which kills thousands of Americans every year. The trial found the vaccine
extended survival for more than 40 patients by several months when compared to 80
other patients who were treated at the same hospitals and received standard therapy –
47 weeks compared to 32 weeks. Several of the patients who received the cancer
vaccine have survived for more than a year. The results suggest that doctors may be
able to extend survival even longer by combining the vaccine with other drugs that
enhance this immune response.
cancer center kudos & facts
FACT
UCSF ranked among the top 12 in the nation for cancer care
in the 2012–2013 U.S. News & World Report “America’s Best
Hospitals” survey.
FACT
The cancer center receives the highest level of research funding from
the National Cancer Institute among cancer centers in California.

your gifts, our thanks
Patricia Rosenberg
(second from left) and her
mother, Grace, celebrate
with the first Rosenberg
fellow, Rahul Aggarwal,
and Charles Ryan.
A Father’s Inspiration Lives On
Ronald Rosenberg faced prostate cancer as he lived life – with an open mind and undaunted
spirit. During his 12-year battle, he developed deep respect and gratitude for his UCSF
oncologist, Charles Ryan, MD. “My dad always believed there would be another arrow in
Dr. Ryan’s quiver,” says his daughter, Patricia Rosenberg. “He saw the strides Dr. Ryan was
making with his research.” Eager to contribute to that knowledge, Rosenberg participated in
two clinical trials. “I have incredible reverence for patients like Ron who are willing to step into
the unknown,” says Ryan. Although Rosenberg ultimately lost his fight, his legacy will live on
through the Ronald A. Rosenberg Endowed Fellowship in Genitourinary Medical Oncology in
the Division of Hematology/Oncology, established with a generous gift from Patricia and the
Rosenberg family. “Training young fellows for a career in research is one of the most important
things that we do,” says Ryan. “The Rosenberg fellows will go on to conduct meaningful
prostate cancer research and train others – the downstream effects will be nearly infinite.”
Donors, Doctor Unite to Beat Blood Cancer
Defeating an intrepid disease calls for uniting the best resources, intellect, and talent. That’s
the power behind the Grand Multiple Myeloma Translational Initiative (MMTI) at UCSF. And it’s
the story of donors John Sanguinetti and Ron Wornick, and MMTI Director Jeff Wolf, MD. The
two men share Wolf’s desire to see new therapies for this blood cancer, which has long proved
extremely challenging to treat. Leveraging UCSF’s deep research expertise from different
disciplines to develop novel treatments is a goal of the MMTI, launched in 2009 with the help of
a generous gift from Stephen and Nancy Grand. Leading hematologist-oncologist Tom Martin,
MD, serves as associate director. “Collaboration is what impressed me about the initiative,” says
Sanguinetti, a 30-year resident of Silicon Valley. “That’s how breakthroughs happen.” Wornick,
a longtime UCSF supporter, was excited by the pace of discovery. “They are very focused and
moving at impressive speed,” he says. “It’s very promising.” Their philanthropy is helping fuel
that progress, says Wolf. “Ron and John have been great partners. We’re in it together.”
Ron Wornick, Jeff Wolf,
and John Sanguinetti
have joined forces against
multiple myeloma.
Edward Conner
survived cancer and
became a doctor,
inspired by his
pediatric oncologist,
Kate Matthay.
Giving in Gratitude for a Son’s Care
One day in October 1986, 13-year-old Edward Conner developed a bad headache. Thanks
to alert physicians David Schindler, MD, and William Gonda, MD, the eighth-grader was at
UCSF and diagnosed with leukemia by that evening. His parents, Ed and Nancy Conner, chose
UCSF because of the reputation of an exceptional young pediatric oncologist, Kate Matthay,
MD. “She exuded confidence and explained everything so well,” recalls Ed Conner. For a
scared young Edward, Matthay “removed the fear of the unknown.” His chemo and radiation
proved successful, and over the years of follow-up care she and the Conner family grew close.
Edward – inspired by Matthay – graduated from UCSF School of Medicine and now develops
drugs for Genentech. He’s also a father to Alison, 6, and Lauren, 4. His grateful parents began
supporting Matthay’s work shortly after that first stressful evening and have donated every
year since. “Their philanthropy has been invaluable,” she says. It’s helped Matthay and her
team to develop new therapies for leukemia, neuroblastoma, and other childhood cancers.
And to see kids like Edward live to have children of their own.
FACT
In 2011, UCSF received $72.8 million in total research support from the
National Cancer Institute.
FACT
Cancer-related research and clinical care are significant priorities for
UCSF; approximately one-quarter of the university’s full-time faculty
members work in cancer research or patient care.

financial highlights
Visionary Circle
Lifetime Giving of $1 Million and Above
Allocation of Philanthropic Support
To cancer programs at UCSF for the fiscal year
ending June 30, 2012
Capital Funds $3,916,050
e.g., Helen Diller Family
Cancer Research Building
Restricted $31,108,836
e.g., to a specific program
Unrestricted $1,466,565
e.g., General Fund
Total $36,491,451
Sources of Philanthropic Support
To cancer programs at UCSF for the fiscal year
ending June 30, 2012
Individuals $11,180,939
Foundations and $17,060,375
Family Foundations
Corporations $6,939,393
Other Organizations $1,310,744
Total $36,491,451
Sources of Philanthropic Support
Yearly summary for fiscal years 2008–2012
Individuals
Foundations and
Family Foundations
Corporations
Other Organizations
$53,089,738
2008
4%
4%
11%
30%
19%
$45,828,912
2009
$42,437,012
2010
85%
47%
$31,913,032
2011
$36,491,451
2012
Anonymous (17)
Accelerate Brain Cancer Cure, Inc.
The Bonnie J. Addario Lung
Cancer Foundation
Estate of Edward S. Ageno
American Association for
Cancer Research
American Brain Tumor Association
American Cancer Society
American Cancer Society
California Division
American Society of Clinical Oncology
Estate of Stanford W. Ascherman
The Atlantic Philanthropies
Martha and H. Brewster Atwater
Roma M. Auerback
Avon Foundation
Ayco Charitable Foundation
Lynne and Marc R. Benioff
Theodora B. Betz Foundation
Bionovo, Inc.
Jane Bishop *
Frances F. Bowes
William K. Bowes, Jr. Foundation
The Breast Cancer
Research Foundation
Linda and Neill H. Brownstein
Carol Franc Buck
Eva Benson Buck Charitable Trust D
Estate of Hildur V. Bullerwell
Christine and Steven A. Burd
Frank A. Campini Foundation
Cancer Research Institute
Champion Charities
Chevron Corporation
Estate of Ruth M. DeBernardi
Donna M. and Kenneth T. Derr
Helen Diller Family Foundation
Ann H. and L. John Doerr III
Estate of Volker Dolch
Carol P. and Michael I. Dollinger
The Dougherty Family Foundation
Greg Dougherty
Nancy Dougherty
Joseph Drown Foundation
The Ellison Medical Foundation
Anne and Jason Farber Foundation, Inc.
Estate of Condina J. Ferro
Fidelity Investments Charitable
Gift Fund
Fisher Families
Foundation for Informed Medical
Decision Making, Inc.
Joseph H. Friend *
Susan M. Geck *
Genentech, Inc.
The Goldhirsh Foundation, Inc.
Richard and Rhoda Goldman Fund
Richard N. Goldman *
Nancy and Stephen Grand
Eva and Andrew Grove
Guzik Foundation
Mimi and Peter Haas Fund
Estate of E. Dixon Heise
Joan and Irwin M. Jacobs
Jewish Community Federation of
San Francisco, the Peninsula, Marin
and Sonoma Counties
Jewish Community Foundation of
San Diego
Kalmanovitz Charitable Foundation
Kazan, McClain, Abrams, Fernandez,
Lyons, Greenwood, Harley &
Oberman Foundation
Kirk Kerkorian
Alison and Arthur H. Kern
Gwen M. and John A. Kerner
Sidney Kimmel Foundation for
Cancer Research
The Susan G. Komen Breast
Cancer Foundation
Deepa N. Iyengar and
Ashok Krishnamurthi
Mary V. Lester and W. Howard Lester *
The Leukemia and Lymphoma Society
The Lincy Foundation
The Listwin Family Foundation
Edmund & Jeannik
Littlefield Foundation
Jeannik Mequet Littlefield
Lucille P. Markey Charitable Trust
Estate of Alicia McEvoy
Estate of Clare C. McEvoy
Estate of Jay D. McEvoy
Nan Tucker McEvoy
Nion T. McEvoy
The Minneapolis Foundation
Estate of Frederick S. Moody Jr.
Betty I. and Gordon E. Moore
Mount Zion Health Fund
Multiple Myeloma Research
Foundation
National Brain Tumor Society
Merillyn J. Noren
Susan and William E. Oberndorf
The Bernard Osher Foundation
Pediatric Brain Tumor Foundation
Jeffrey and Karen Peterson
Family Foundation
Estate of Kathleen Mahoney Plant
Catherine and Michael Podell
Helen * and Sol * Price
Prospect Creek Foundation
Prostate Cancer Foundation
Radiology Research and
Education Foundation
Estate of Mary Ann Radovich
George R. Roberts
Estate of Mario J. Rocca
Toni Rembe and Arthur Rock
Rombauer Family
Damon Runyon Cancer
Research Foundation
Safeway, Inc.
Safeway Foundation Northern
California Division
The San Francisco Foundation
San Francisco General
Hospital Foundation
Schwab Charitable Fund
Bernard Lee Schwartz Foundation, Inc.
Estate of Jack Douglas Shand
William L. Siebrandt
Sandra Lloyd and W. Douglass Smith
Elle and Paul H. Stephens
Alexander and Margaret Stewart Trust
The V Foundation for Cancer Research
Eddi and Wendell Van Auken
Vanguard Charitable
Endowment Program
Angela C. Wang
Dana A. Corvin and Harris Weinberg
Robert K. Werbe *
Diana S. * and Herschel S. * Zackheim
FACT
The cancer center’s more than 370 members and associate
members exemplify the value of attacking the cancer problem
through collaborative, interdisciplinary research.
*deceased

0906
University Development and Alumni Relations
UCSF Box 0248
San Francisco, CA 94143-0248
Address service requested
Possibilities for Partnership
To learn more about our cancer center priorities, please contact:
Suzanne Teer, Executive Director of Development
415/476-3622
steer@support.ucsf.edu
UCSF Box 0248, San Francisco, CA 94143-0248
support.ucsf.edu
Produced by the UCSF Office of University Development and Alumni Relations
Editor: Anne Kavanagh
Writers: Claire Conway, Anne Kavanagh
Design: Audrey Feely
Cover Illustration: Barry Taylor et al; Science Magazine Photography: Noah Berger, Cindy Chew, Jon Drum, Elisabeth Fall
© 2012 The Regents of the University of California
We’ve Gone Green!
Please visit us online to view a complete list of FY11-12 donors:
support.ucsf.edu/cancer/honor-roll